arrow
Back
J

John Wilding

Aintree University Hospital

95H-index
736Paper Count
5.6WCitation Count
Published Papers 249
Publication Date
Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management
err2026-07-13
err0
errOAAI
errPhilip Newland-Jones; Partha Kar; Beth Kelly; Rahul Mohan; Sarah Davies; Jane Diggle; Marc Evans; Kevin Fernando; Debbie Hicks; Naresh Kanumilli; Nicola Milne; Dipesh Patel; Samuel Seidu; Adie Viljoen; David C. Wheeler; John P. H. Wilding
errShare
errSave
Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
err2026-04-27
err0
errOAAI
errJan Oscarsson; Monika Huhn; Yunyun Jiang; Ingrid Gause-Nilsson; Stephen D. Wiviott; Filipe A. Moura; John P. H. Wilding; Simona Cernea; Luc Van Gaal; Avivit Cahn; Deepak L. Bhatt; Peter A. Johansson; C. David Sjöström
errShare
errSave
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study
err2026-04-22
err0
errOAAI
errLieven Annemans; Erin Johansson; Erik Spaepen; Naomi van Hest; Josephine Grist; Sarah Zimner-Rapuch; John P. H. Wilding
errShare
errSave
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
err2026-04-21
err0
errOAAI
errErin Johansson; John P. H. Wilding; Navneet Upadhyay; Naomi van Hest; Myles Kirk; Erik Spaepen; Sarah Zimner-Rapuch; Lieven Annemans; Harold Bays
errShare
errSave
errShare
errSave
Clinical and Preclinical Obesity in Korean Adults from 2014 to 2023
err2026-01-01
err1
errOAAI
errChoe, Hun Jee; Despres, Jean-Pierre; Wilding, John P. H.; Ryan, Donna H.; Lim, Soo
errShare
errSave
Tirzepatide and the NHS: are we creating atwo-tier obesity treatment system?
err2025-11-01
err0
errOAAI
errDobbie, Laurence J.; Molokhia, Mariam; Wilding, John Ph; Tan, Tricia M-M; McGowan, Barbara
errShare
errSave
Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58
err2025-09-15
err0
errOAAI
errPaul M. Haller; Stephen D. Wiviott; David D. Berg; Petr Jarolim; Erica L. Goodrich; Deepak L. Bhatt; Ingrid Gause-Nilsson; Lawrence A. Leiter; Darren K. McGuire; John P.H. Wilding; Itamar Raz; Marc S. Sabatine; David A. Morrow
errShare
errSave
Rising to the challenges of research in multiple long-term conditions: health and social care research ecosystem approaches
err2025-09-14
err0
errOAAI
errDe Soyza, Anthony; Goodwin, Victoria A.; Roberts, Kate; Masoli, Jane; Mathews, Jacqueline; Wilding, John; Nestor, Gary; Bower, Peter
errShare
errSave
Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England
err2025-09-01
err0
errOAAI
errde Bray, Anne; Schnitzer, Hanna; Mahase, Elisabeth; Singh, Puspha; Andrews, Rob; Mcgowan, Barbara M.; Le Brocq, Sarah; Wilding, John P. H.; Flint, Stuart W.; Hazlehurst, Jonathan M.
errShare
errSave
Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study)
err2025-08-22
err0
PREAI
errWerd Al-Najim; Babak Dehestani; Ahmed W. Al-Humadi; Danielle H. Bodicoat; Dimitris Papamargaritis; Michael Lean; Barbara McGowan; David R. Webb; John PH Wilding; Melanie J. Davies; Carel W. le Roux
errShare
errSave
Defective lymphatic vasculature in obesity
err2025-03-27
err0
errOAAI
errJingjing Zhu; John P. H. Wilding; Ji Hu
errShare
errSave
Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials
err2025-02-28
err0
errOAAI
errRasouli, Neda; Wilding, John P. H.; Kwan, Anita Y. M.; Paik, Jim S.; Sharma, Palash; Peleshok, Jennifer
errShare
errSave
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
errOBESITY
IF4.7
err2025-02-13
err0
errOAAI
errKushner, Robert F.; Ryan, Donna H.; Deanfield, John; Kokkinos, Alexander; Cercato, Cintia; Wilding, John; Burguera, Bartolome; Wu, Chau-Chung; Craciun, Anca-Elena; Pall, Denes; Hramiak, Irene; Hjelmesaeth, Joran; Harder-Lauridsen, Nina M.; Weimers, Petra; Jeppesen, Ole Kleist; Kallenbach, Klaus; Lincoff, A. Michael; Lingvay, Ildiko
errShare
errSave
Galectin-3 and Progression of Kidney Disease in Patients With Type 2 Diabetes Mellitus: Analyses From the DECLARE-TIMI 58 Trial
err2024-11-12
err0
PREAI
errHaller, Paul; Wiviott, Stephen; Berg, David; Jarolim, Petr; Goodrich, Erica; Bhatt, Deepak; Cahn, Avivit; Gause-Nilsson, Ingrid; Leiter, Lawrence; McGuire, Darren; Raz, Itamar; Wilding, John; Sabatine, Marc; Morrow, David
errShare
errSave
The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes
err2024-11-11
err0
errOAAI
errRiley, David R.; Henney, Alex; Anson, Matthew; Hernadez, Gema; Zhao, Sizheng S.; Alam, Uazman; Wilding, John P. H.; Craig, Sonya; Cuthbertson, Daniel J.
errShare
errSave